Fortune 500

By: mohamed badrawy

 Classify Companies By Country
Country # Country # Country #
1-AUSTRALIA 8 14-INDIA 8 27-SOUTH KOREA 10

2-AUSTRIA 3 15-IRELAND 2 28-SPAIN 10

3-BELGIUM 5 16-ITALY 11 29-SWEDEN 5

4- 1 17-JAPAN 71 30-SWITZERLAND 15
BELGIUM/NETHE
RLAND
5-BRAZIL 7 18-LUXEMBOURG 1 31-TAIWAN 8

6-BRITIAN 29 19-MAYLASIA 1 32-THAILAND 1

7- 1 20-MEXICO 2 33-TURKEY 1
BRITIAN/NETHER
LAND
8-CANADA 11 21-NETHERLANDS 13 34-U.S 139

9-CHINA 46 22-NORWAY 1 35-VENEZUELA 1

10-DENMARK 2 23-POLAND 1

11-FINLAND 1 24-RUSSIA 6

12-FRANCE 39 25-SAUDI ARABIA 1

13-GERMANY 37 26-SINGAPORE 2
 Classify By Regions

REGION No. of Companies

AMERICAS 160

ASIA PACIFIC & AUSTRALIA 157

EUROPE 183
 AMERICA’S

COUNTRY NO. OF COMPANIES

BRAZIL 7
CANADA 11
MEXICO 2
U.S 139
VENEZUELA 1
 ASIA PACIFIC
COUNTRY NO. OF COMPANIES
AUSTRALIA 8
CHINA 46
INDIA 8
JAPAN 71
MALAYSIA 1
SAUDI ARABIA 1
SINGAORE 2
SOUTH KOREA 10
TAIWAN 8
THAILAND 1
TURKEY 1
 EUROPE
COUNTRY NO. OF COUNTRY NO. OF
COMPANIES COMPANIES
AUSTRIA 3 ITALY 11

BELGIUM 5 LUXEMBOURG 1

BELGIUM/NETH 1 NETHERLANDS 13
ERLANDS
BRITAN 29 NORWAY 1

BRITAIN/NETH 1 POLAND 1
ERLANDS
DENMARK 2 RUSSIA 6

FINLAND 1 SPAIN 10

FRANCE 39 SWEDEN 5

GERMANY 37 SWITZERLAND 15

IRELAND 2
 Classify By Industry
Industry % change from Industry % change
2007 from 2007

Food Production 48.8 Telecommunications 9.8

Energy 34.9 Household and Personal Products 9.6
Petroleum Refining 27.8 Food and Drug Stores 9
Diversified Financials 27.1 Building Materials, Glass 7.1
Metals 25.5 Banks: Commercial and Savings 7
Engineering, Construction 22.4 Aerospace and Defense 6.8
Network and Other Communications
Mining, Crude-Oil Production 21.2 Equipment 6.2
Utilities 19.4 Wholesalers: Health Care 5.8
Beverages 19.3 Mail, Package, and Freight Delivery 5.7
Trading 15.9 Entertainment 5.5
Shipping 14.3 Pharmaceuticals 4.9
Chemicals 13.9 General Merchandisers 4.8
Industrial Machinery 13.3 Computers, Office Equipment 4.1
Specialty Retailers 12.5 Airlines 1.9
Food Consumer Products 10.7 Electronics, Electrical Equip. 0.6
Telecommunications 9.8 Insurance: Property and Casualty (Stock) -2.3
Household and Personal
Products 9.6 Insurance: Life, Health (stock) -2.4
Food and Drug Stores 9 Motor Vehicles and Parts -3.6
Health Care: Insurance and
Managed Care 8.4
 Pharmaceuticals
 Top 5 companies:
1-Johnson & Johnson

2-Pfizer

3-GalaxoSmithKline

4-Roche Group

5-Sanofi-Aventis
 MISSION (CREDO) :
Our Credo We believe our first responsibility is to the doctors, nurses and
patients, to mothers and fathers and all others who use our products and services.
In meeting their needs everything we do must be of high quality. We must
constantly strive to reduce our costs in order to maintain reasonable prices.
Customers’ orders must be serviced promptly and accurately. Our suppliers and
distributors must have an opportunity to make a fair profit. We are responsible to
our employees, the men and women who work with us throughout the world.
Everyone must be considered as an individual. We must respect their dignity and
recognize their merit. They must have a sense of security in their jobs.
Compensation must be fair and adequate, and working conditions clean, orderly
and safe. We must be mindful of ways to help our employees fulfill their family
responsibilities. Employees must feel free to make suggestions and complaints.
There must be equal opportunity for employment, development and advancement
for those qualified.
 We must provide competent management, and their actions must be just
and ethical. We are responsible to the communities in which we live and
work and to the world community as well. We must be good citizens-
support good works and charities and bear our fair share of taxes. We
must encourage civic improvements and better health and education. We
must maintain in good order the property we are privileged to use,
protecting the environment and natural resources. Our final responsibility
is to our stockholders. Business must make a sound profit. We must
experiment with new ideas. Research must be carried on, innovative
programs developed and mistakes paid for. New equipment must be
purchased, new facilities provided and new products launched. Reserves
must be created to provide for adverse times. When we operate according
to these principles, the stockholders should realize a fair return.
Product Mix:

Three segments:-
•Consumer

•Pharmaceutical

•Medical Devices and Diagnostics Consumer

Consumer Products:
1) Baby Care

2) Skin & Hair Care

3) Wound Care & Topical

4) Oral Health Care

5) Women’s Health

6) Over-the-counter Medicines

7) Nutritionals

8) Vision Care
Medical Devices & Diagnostics
1) Orthopaedics
2) Implants
3) Joint Replacements
4) Sports Medicine and trauma
5) Heart & Vascular Disease
6) Coronary Artery Disease
7) Peripheral Vascular And
Obstructive Disease
8) Neurological Disease
9) Arrhythmias
10) Diabetes
11) Self-Measured Blood Glucose
Monitors
12)Insulin Delivery Devices
13) Medical Diagnostics
14) Blood Screening
15) Clinical Lab Equipment
16) Diagnostic Tests & Molecular
Diagnostics
17) Vision Care
18) General Surgery
19) Bariatric Surgery Of Obesity
20) Urologic Surgery
21) Hernia Surgery
22) Women’s Health & Urology
23) Plastic Surgery
24) Surgical Instruments and Infection
Prevention
The Pharmaceutical segment's broad portfolio focuses on unmet
medical needs across several therapeutic areas: oncology;
infectious disease; immunology; neuroscience;
cardiovascular and metabolism. It includes products in the
anti-infective, antipsychotic, cardiovascular, contraceptive,
dermatology, gastrointestinal, hematology, immunology,
neurology, oncology, pain management, urology and
virology fields. Below are some of our main products.
OUR ENDURING STRENGTHWITH THE CHALLENGES OF 2010, AND
WITHIN THE CONTEXT OF OUR 125TH ANNIVERSARY IN 2011, WE ARE
REMINDED MORE THAN EVER OF OUR HERITAGE. UNWAVERING
COMMITMENT TO THE PRINCIPLES EMBODIED IN OUR CREDO AND AN
APPRECIATION FOR THE ELEMENTS OF OUR OPERATING MODEL ARE AS
STRONG TODAY AS AT ANY TIME IN OUR HISTORY.WE ARE NOT PERFECT;
WE WILL MAKE MISTAKES. AND WHEN WE DO, WE HOLD OURSELVES
ACCOUNTABLE TO CORRECT THEM. THAT ACCOUNTABILITY IS
INHERENT IN OUR CREDO. ITS TENETS DEMAND A SPECIAL LEVEL OF
RESPONSIBILITY … FIRST TO PATIENTS AND CUSTOMERS, THEN TO OUR
EMPLOYEES, OUR COMMUNITIES AND OUR SHAREHOLDERS. OUR
CREDO REMAINS OUR NORTH STAR.ANOTHER ENDURING STRENGTH IS
THE CHARACTER OF THE PEOPLE OF JOHNSON & JOHNSON. DESPITE
DIVERSE BUSINESSES, WE ARE UNITED BY AN EXTRAORDINARY BOND
—A COMMITMENT TO CARING FOR ONE PERSON AT A TIME AND
TOUCHING THE WORLD—ORIGINATING FROM OUR CREDO VALUES. IT IS
A QUIET SENSE OF PURPOSE FOCUSED AROUND THE LIVES WE AFFECT,
THE FAMILIES AND CHILDREN WE TOUCH, AND THE PROFESSIONALS
WHO SUPPORT THEIR HEALTH.OUR PRODUCTS, OUR PIPELINE AND OUR
GLOBAL PRESENCE MAKE US STRONG AS A COMPANY. OUR PEOPLE AND
OUR CREDO SET US APART.
Pfizer Mission Statement:

"We will become the world's most valued company to patients, customers, colleagues,
investors, business partners, and the communities where we work and live."
Product Mix

1)Human Health

a) OTC Products
b) Prescription Products

2) Animal Health
To maximize new opportunities in biomedical research, and bring more innovative
medicines to more patients more quickly, Pfizer has created two distinct research
organizations. The PharmaTherapeutics Research & Development Group focuses on
the discovery of small molecules and related modalities; and The BioTherapeutics
Research & Development Group focuses on large-molecule research, including
vaccines.Pfizer has also developed an enhanced commercial operating structure.
Pfizer has nine diverse health care businesses: Primary Care, Specialty Care,
Oncology, Emerging Markets, Established Products, Consumer Healthcare, Nutrition,
Animal Health and Capsugel. Each of these businesses is led by an executive with
clear accountability for results - from product development following proof of concept
to providing access to patients and through to the end of the product's life cycle. The
businesses are provided with the resources to pursue attractive growth opportunities
and to deliver benefits to all who rely on us around the world.With this structure, we
are able to rapidly capitalize on opportunities to advance our business by increasing
support for successful new medicines, forging partnerships with key customers,
entering into co-promotion and licensing agreements, investing in new technologies to
add value to our core product offerings, and acquiring new products and services from
outside the company.
MISSION:
The pharmaceutical industry is experiencing a time of unprecedented challenge.
Patent expiries, regulatory issues and increased pressures from healthcare
providers have combined to create an environment where our sector is
associated with lower growth and higher risk. We are addressing these
challenges through three key strategic priorities that we believe will transform
GSK into a company that delivers more growth, less risk and an improved
financial performance.
Product Mix

1-Prescription medicines
2-Consumer Healthcare
3-Vaccines
4-Stieffel
Three strategic priorities in 2008, we established the following three strategic
priorities:

• Grow a diversified global business

• Deliver more products of value
• Simplify the operating model Announcing GSK’s 2009 Annual Results, CEO
Andrew Witty said, "Our strategy is delivering and I believe that GSK is now
moving to a position where we can deliver our goal of long-term sustainable
financial performance. 2009 saw GSK return to sales growth and I am confident
of our prospects on 2010".
Roche maintains open and honest relationships with our shareholders, prospective
investors and the wider investment community. The role of Investor Relations is to
manage these relationships efficiently, transparently and consistently in accordance
with company polices and relevant securities rules and laws. Our goals are to:

• Provide timely, relevant, consistent and accurate information to all shareholders

and prospective investors to aid them in assessing the value of Roche and to make
informed investment decisions

• Facilitate dialogue between Roche management and the investment community

• Achieve a fair valuation of Roche by the financial markets

A) Pharmaceuticals
1- Oncology
2-Virology
3-Inflammation
4-Metabolic Disorders
5-Central Nervous System

B) Solutions for Diagnostics

C) Products for Researchers

Where we are today Today Roche ranks among the world’s leading healthcare companies
and has two strong core businesses: diagnostics and pharmaceuticals. Serving Patients and
Customers Roche’s prime objective is to identify and meet the patient’s and customers’
needs. This implies solving their problems and anticipating their future needs by
maintaining close contact with them and listening to what they say.  At Roche we focus our
resources on two research intensive businesses: pharmaceuticals and diagnostics. Within
these businesses we priorities those areas of significant unmet need where we have the
expertise to make a difference. Our aim is to develop new and improved drugs, diagnostic
tests and services offering significant benefits over existing options. Focusing on Innovation
By innovation we mean the creation and commercialization of medically differentiated
products and services that lead to a tangible improvement to the health, quality and length of
patients’ lives. As a research-focused company we exploit the latest discoveries and
technologies to develop our products. This is why Roche invested over 9 billion Swiss
francs in 2010 on research and development. Roche continues its longstanding tradition of
working in alliances with some of the most forward-looking and technologically advanced
companies in the world. Roche invests heavily in biotechnology and is the world’s largest
biotechnology company.
Where we’re going Personalized Healthcare Two patients can have the same diagnosis
yet respond in different ways to the same medicine. One patient may be helped by
treatment, while the other experiences unwanted side effects without the desired
clinical benefit. Some of this variability is due to genetic and other biological differences
between patients. The idea of personalized healthcare is to use insights into these
differences at the molecular level to develop treatments and tests tailored to the needs
of specific patient populations. This has enormous potential to make healthcare better,
safer and more cost-effective. It will be a while before this potential is fully realized, but
the market is clearly shifting away from ‘one size fits all’ products. Roche is a driving
force behind this trend and already has several personalized healthcare products on the
market. One important aspect of personalizing medicine is the close interaction
between pharmaceuticals and diagnostics. The fact that we are leaders in both these
areas is a source of competitive advantage when it comes to meeting the healthcare
challenges of the future.
As a company, AstraZeneca US is committed to a mission of improving human
health.
The people of AstraZeneca are dedicated to:

• Discovering, developing, and delivering innovative, meaningful medicines and

other healthcare solutions that help enrich the lives of patients, as well as their
families and communities

• Putting the health of patients first by providing educational programs, resources,

and tools designed to help empower and inform

• Creating a challenging and rewarding work environment that inspires our

employees
Seven major therapy areas Sanofi-aventis focuses its activities on:

Cardiovascular medicine
Thrombosis
Oncology
internal medicine
metabolic disorders
diseases of the central nervous system
vaccines
We share a strong set of values on which our individual and Group performance are
founded. Upheld daily by each of us through our actions and initiatives, we work for
what really matters: health.
Audacity-Creativity-Respect-Courage-Solidarity-Performance

The seven therapy areas in which we specialize - cardiovascular disease, thrombosis,

oncology, central nervous system disorders, metabolic disorders, internal medicine
and vaccines - are among those prioritized by government in its Health of the Nation
objectives. Our dedicated Healthcare Development Managers work closely with NHS
Trusts and leading medical experts all over the UK to optimize access to our products
for those who stand to benefit the most and to help patients and clinicians gain
greater understanding of the medical conditions concerned. As well as playing an
active role in a wide range of healthcare charities, patient associations, scientific
societies and other healthcare organizations, sanofi-aventis contributes directly to the
development and implementation of the government's National Service Frameworks.
Thank You